Although corticotropin-releasing hormone (CRH), a regulator of stress responses, acts through two receptors (CRH 1 and CRH 2 ), the role of CRH 2 in stress responses remains unclear. Knock-out mice without the CRH 2 gene exhibit increased stress-like behaviors. This profile could result either directly from the absence of CRH 2 receptors or indirectly from developmental adaptations. In the present study, CRH 2 receptors were acutely blocked by ␣-helical CRH (␣hCRH, CRH 1 /CRH 2 antagonist; 0, 30, 100, and 300 ng) infusion into the lateral septum (LS), which abundantly expresses CRH 2 but not CRH 1 receptors. Freezing, locomotor activity, and analgesia were tested after infusion. Intra-LS ␣hCRH blocked shock-induced freezing without affecting activity or pain responses; infusions into lateral ventricle or nucleus of the diagonal band had no effects. The same behavioral profile was obtained with D-Phe-CRH (12-41) (100 ng), another CRH 1 /CRH 2 antagonist. A selective CRH 1 antagonist (NBI27914), in doses that reduced freezing on intra-amygdala (central nucleus) infusion (0, 0.2, and 1.0 g), did not affect freezing when infused into the LS. Ex vivo autoradiography revealed that binding of [ 125 I]sauvagine, a mixed CRH 1 /CRH 2 agonist, was prevented in the LS by previous intra-LS infusion of ␣hCRH but not NBI27914. In vitro studies demonstrated that [
Corticotropin-releasing hormone (CRH) coordinates various aspects of the stress response (Vale et al., 1981) . CRH elicits behaviors normally exhibited in response to stress, whereas CRH receptor antagonists prevent stress-induced behaviors (Koob and Heinrichs, 1999) . Patients with stress-related problems such as depression often have alterations in their CRH system, suggesting that it may play an important role in stress-related psychopathology (Nemeroff et al., 1984; Mitchell, 1998) .
Recently, CRH receptor antagonists have been developed as a novel class of anxiolytics and antidepressants (McCarthy et al., 1999) . A preliminary open-label clinical trial indicated that these compounds alleviate symptoms in depressed patients (Zobel et al., 2000) . Although there are two cloned CRH receptors (CRH 1 and CRH 2␣,␤,␥ ), most studies suggesting that CRH receptor antagonists may be psychotherapeutic agents have focused on the CRH 1 subtype, perhaps because highly selective nonpeptide antagonists for CRH 2␣ receptors (splice variant expressed in brain) have not been identified (Perrin and Vale, 1999) . Nonetheless, the very recent discovery of endogenous and highly selective CRH 2 -receptor ligands in rodent and human brain suggests that this receptor may play some intrinsic functional role (Hsu and Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001) . Nonetheless, the role of CRH 2␣ receptors in stress and anxiety remains unclear.
Antisense oligonucleotides have been used to study CRH 2␣ receptor functioning in stress; however, interpretation of these studies is difficult, because they failed to demonstrate an appreciable reduction in CRH 2␣ receptors after oligonucleotide infusion (Heinrichs et al., 1997; Liebsch et al., 1999) . Paradoxically, knock-out studies indicate that deletion of the CRH 2␣ gene produces a phenotype characterized by increased anxiety-like behaviors (Bale et al., 2000; Coste et al., 2000; Kishimoto et al., 2000) . One problem with interpreting these studies, however, is that the observed phenotype could be attributable to indirect developmental alterations resulting from the mutation rather than being a direct result of the gene deletion (Gingrich and Hen, 2000) . Measurement of stress-related behavior after acute antagonism of CRH 2␣ receptors circumvents these confounds.
The distributions of CRH 1 and CRH 2␣ receptors in rodent brain are mostly nonoverlapping (Chalmers et al., 1995; Primus et al., 1997) , suggesting that the role of CRH 2␣ receptors in stress might be determined by antagonizing CRH receptors in a brain region selectively expressing the CRH 2␣ receptor subtype. The lateral septum (LS) contains a high density of CRH 2␣ receptors but is devoid of CRH 1 receptors (Chalmers et al., 1995; Primus et al., 1997) . Although learning a conditioned fear response involves CRH receptors in the LS (Lee, 1995; Radulovic et al., 1999) , a selective role for the CRH 2␣ receptor subtype in stress-induced behavior remains unclear.
The present studies tested the hypothesis that CRH 2␣ receptor blockade in the LS would decrease stress-induced behavior by determining whether intra-LS infusion of ␣hCRH or D-Phe-CRH , CRH 1 /CRH 2 receptor antagonists, reduced shockinduced freezing, a CRH-receptor-mediated defensive behavior displayed in response to fear (Kalin et al., 1988; Swiergiel et al., 1992 Swiergiel et al., , 1993 . Effects of ␣hCRH on other behaviors or in neighboring regions were measured to assess the behavioral and anatomical specificity of LS-mediated effects. Receptor subtype specificity of LS-mediated effects was determined by comparing the effects of CRH 1 /CRH 2 antagonists with those of a selective CRH 1 antagonist, NBI27914 (Chen et al., 1996) . Of particular interest was whether acute antagonism of CRH 2␣ receptors would produce a different behavioral profile than that seen after CRH 2␣ gene knock-out.
MATERIALS AND METHODS Animals
One hundred seventy-four male Sprague Dawley rats (Charles River Laboratories) were used in the present studies. Rats were housed in pairs in clear plastic cages in a temperature-and humidity-controlled vivarium and were maintained on an ad libitum diet of lab chow (Harlan Teklad, Madison, W I) and water. Lights in the animal colony came on at 7 A.M. and turned off at 7 P.M.; all testing occurred between 11 A.M. and 4 P.M. On arrival, rats were handled gently by the experimenter to minimize stress during the experiments. Animal facilities were approved by the Association for the Assessment and Accreditation of Laboratory Animal C are; protocols were in accordance with the Guiding Principles in the C are and Use of Animals provided by the American Physiological Society and the guidelines of the National Institutes of Health. All efforts were made to prevent animal suffering and minimize the number of animals used for the studies.
Surgery
Within 1 week of arrival, animals were anesthetized with sodium pentobarbital (65 mg / kg; Butler Co., Columbus, OH), treated with 0.1 ml of atropine sulfate (Phoenix Pharmaceuticals, St. Joseph, MO) to minimize respiratory distress, and placed into a stereotaxic apparatus (Kopf Instruments, T ujunga, CA). Stainless steel cannulas (23 gauge) were implanted bilaterally and affixed to the skull with dental cement (Lang Dental, Wheeling, IL) and skull screws (Small Parts, Miami Lakes, FL). C annulas were aimed at the L S [coordinates were anteroposterior (AP), ϩ0.4 mm from bregma; lateromedial (L M), Ϯ0.8 mm from midline, and dorsoventral (DV), Ϫ3.5 mm from skull surface], the lateral ventricle (LV; coordinates were AP, Ϫ0.4 mm from bregma; L M, Ϯ1.5 mm from midline; and DV, Ϫ2.2 mm from skull surface), the nucleus of the diagonal band (N DB; coordinates were AP, ϩ0.4 mm from bregma; L M, Ϯ0.8 mm from midline; and DV, Ϫ3.5 mm from skull surface), or the central nucleus of the amygdala (C eA; coordinates were AP, Ϫ2.5 mm from bregma; L M, Ϯ4.2 mm from midline; and DV, Ϫ5.2 mm from skull surface) (all coordinates based on the atlas of Paxinos and Watson, 1998) . After surgery, rats were allowed 5-7 d to recover, during which time daily health checks were performed by the experimenter.
Drugs
␣-Helical CRH (␣hCRH) and were obtained from Bachem-Peninsula Laboratories (Torrance, CA) and were dissolved in sterile distilled water, pH 6.5. Thus, the vehicle treatment for all experiments in which ␣hCRH and D-Phe-CRH were administered was distilled water, pH 6.5. N BI27914 was synthesized at Neurocrine Biosciences (Chen et al., 1996) and dissolved with sonication in a vehicle solution of 90% distilled water, 5% ethanol, and 5% cremophor EL (Sigma, St. L ouis, MO). This vehicle solution was used as the control treatment for all experiments in which N BI27914 was administered into the brain. All doses (see below) were calculated using the HC l salt weight.
Microinfusion procedure
On all test days, animals were gently held, and their stylets were removed and placed into 70% ethanol. C annulas were cleaned with a dental broach, and stainless steel injectors (30 gauge) were lowered so that they extended 1.5-5 mm below the tips of the cannulas. Thus, the final DV coordinates from skull surface were Ϫ6.0 mm for the L S, Ϫ3.7 mm for the LV, Ϫ8.5 mm for the N DB, and Ϫ8.2 mm for the C eA. The injectors were attached to polyethylene tubing, which was connected to 10 l Hamilton microsyringes (Fisher Scientific, Pittsburgh, PA) that were mounted on a motorized pump (Harvard Apparatus, Holliston, M A). A total of 0.5 l of vehicle or drug per side was delivered over 93 sec in each inf usion. The pump was then shut off, and injectors were kept in place for an additional 60 sec to allow for absorption of the injection bolus into the tissue. Injectors were then removed; stylets were replaced; and animals were placed immediately into chambers for behavioral testing. T wo to 3 d before drug testing, all rats received a mock inf usion in which injectors were lowered but no solution was delivered to acclimate rats to the inf usion procedure and to minimize stress attributable to injections on the test days.
Behavioral Testing
After drug inf usions, rats were tested in one of the three following behavioral paradigms. For all studies, rats were placed into the behavioral testing apparatus immediately after drug inf usion. The experimenter was blind to the treatment condition of the rats for all testing.
Shock-induced f reezing. Rats were placed individually in a black Plexiglas chamber (21 ϫ 11 ϫ 6 inches) with a metal floor grid and overhead houselights (San Diego Instruments, La Jolla, CA). After a 2 min acclimation period to the chamber, three mild foot shocks were delivered (1 sec, 1.5 mA, separated by 20 sec). The onset and duration (in seconds) of freezing behavior (cessation of all body movements except that required for respiration) were rated for 15 min immediately after the final shock. To be counted as a bout of freezing, freezing behavior had to occur continuously for a minimum of 5 sec. This criterion was applied to minimize the possibility of obtaining spurious counts of freezing.
Locomotor activit y. Rats were placed individually in clear polycarbonate cages (19 ϫ 10.5 ϫ 8 inches) equipped with computer-interfaced photocells along their long axis and cage top to measure unconditioned locomotor activity (San Diego Instruments). Rearing (vertical activity, total cage top photobeam breaks), ambulation (number of cage crossings), and total activity (total photobeam breaks) were recorded over 20 min to match the time course of the freezing test.
Analgesia. Rats were placed individually on a metal plate (prewarmed to 50°C) within a clear Plexiglas chamber (11 ϫ 11 ϫ 8 inches). The latency (in seconds) for the rat to lick its hindpaws after placement onto the plate was recorded. If licking did not occur, rats were removed by the experimenter after 60 sec had elapsed; these animals were given a score of 60.
Experimental design
Eleven experiments were conducted in separate groups of rats.
Effects of intra-LS CR H 1 /CR H 2 antagonists on shock-induced f reezing. In experiment 1, rats were given inf usions of either vehicle (distilled water; n ϭ 10) or ␣hCRH (30 ng; n ϭ 10) into the L S and placed into the freezing apparatus. In experiment 2, rats received either vehicle (n ϭ 12) or a higher dose of ␣hCRH (100 ng; n ϭ 12) into the L S and were tested for shock-induced freezing. In experiment 3, either vehicle (n ϭ 6) or 300 ng of ␣hCRH (n ϭ 6) was inf used into the L S before testing in the freezing apparatus. The doses of ␣hCRH used in the present experiments were chosen on the basis of previous reports that inf usion of 100 -200 ng of this antagonist per side into either the locus ceruleus or amygdala reduces shock-induced freezing (Swiergiel et al., 1992 (Swiergiel et al., , 1993 . Finally, an additional experiment was performed to confirm that a different more potent CRH 1 /CRH 2 antagonist would have the same effects on freezing as ␣hCRH. Thus, in experiment 4, either vehicle (n ϭ 8) or 100 ng of (Menzaghi et al., 1994) (n ϭ 7) was inf used into the L S, and rats were then tested for shock-induced freezing. In this experiment, a 1.0 mA shock intensity was used instead of 1.5 mA to ascertain that baseline latency and duration of freezing in vehicletreated rats were not influenced by this difference in shock intensity.
Effects of intra-LS CR H 1 /CR H 2 antagonists on locomotor activit y and analgesia. Because potential changes in freezing may not necessarily reflect changes in stress-induced behavior but rather may simply be an artifact of altered motor activity levels or pain responses caused by the drug, the effects of CRH 1 /CRH 2 antagonists on baseline locomotor activity and analgesia were tested. Thus, in experiment 5, rats were given a wide dose range of ␣hCRH (0, 30, 100, or 300 ng; n ϭ 11) into the L S and placed into photocell cages. All animals received all ␣hCRH doses in a counterbalanced order over 4 test days. All rats had been habituated to the test cages and inf usion procedure a few days before testing; successive tests were separated by 3 d. In a separate set of rats that were naive to the testing chambers, the effects of D-Phe-CRH (12-41) (0 or 100 ng; n ϭ 6 per group) were evaluated to corroborate ␣hCRH findings and also to be certain that the rat's level of familiarity with the given testing chamber did not influence the CRH antagonist-induced effects (experiment 6). In this experiment, rats were tested only once, and separate animals were used for the different treatment groups so that all testing would occur on the first day that the rats were introduced to the testing chamber; this protocol was chosen to match that of the freezing experiments. In experiment 7, rats were tested for potential changes in pain sensitivity after receiving intra-L S inf usion of ␣hCRH (0 or 100 ng). Testing was conducted over 2 test days that were separated by 1 week. On the first test day, half of the rats received vehicle, and the other half got ␣hCRH before being placed onto the hotplate. One week later, this protocol was repeated, balancing the treatments such that animals that had previously received ␣hCRH got vehicle and rats that previously received vehicle got ␣hCRH. Three separate sets of rats were used for this experiment: one was tested 3 min after the inf usions (n ϭ 7; to correspond to the time point at which shock was delivered in the freezing paradigm); another was tested 10 min after the inf usions (n ϭ 6); and the final group was tested 15 min after the inf usions (n ϭ 5). These different time points were selected to map out the duration of the freezing test and to determine whether there were any alterations in pain sensitivity produced by ␣hCRH at any time during this 15 min period.
Effects on shock-induced f reezing of ␣hCR H inf usion into reg ions neighboring the LS.
To confirm that the behavioral effects observed after intra-L S inf usion of ␣hCRH were localized specifically to the L S and not attributable to diff usion of the drug to other areas, the effects on freezing of ␣hCRH inf usion into regions neighboring the L S were determined. Because the L S is bordered by the lateral ventricle, experiment 8 was performed to determine whether direct intra-LV inf usion of ␣hCRH in the present dose range would affect freezing. The same protocol as in experiment 2 was used, except that intracranial inf usions were made into the LV (vehicle, n ϭ 9; 100 ng of ␣hCRH, n ϭ 9). E xperiment 9 was also identical to experiment 2, except that inf usions were delivered into the N DB (vehicle, n ϭ 8; 100 ng of ␣hCRH, n ϭ 10). The N DB is ventrally adjacent to the L S.
Effects of a selective CR H 1 antagonist on shock-induced f reezing. To determine the receptor subtype specificity of L S-mediated effects, the effects of intra-L S inf usion of a selective CRH 1 antagonist (N BI27914; CRH 1 :CRH 2␣ affinity, Ͼ10,000; Chen et al., 1996) were measured. First, to identif y a dose of N BI27914 that is sufficient to block shock-induced freezing after intracranial administration, several doses of the CRH 1 antagonist were inf used into the C eA, a structure that contains high levels of the CRH 1 receptor subtype and through which ␣hCRH reduces shock-induced freezing (Swiergiel et al., 1993) . Thus, in experiment 10, rats received either vehicle (n ϭ 6) or 0.2 g (n ϭ 6) or 1.0 g (n ϭ 7) of N BI27914 into C eA before testing in the freezing apparatus. Because the 1 g dose was found to potently reduce shock-induced freezing, this dose was used for the L S experiment. Thus, in experiment 11, rats were given either vehicle (n ϭ 7) or 1.0 g of N BI27914 (n ϭ 7) into the L S and were then placed in freezing chambers. At the end of the shockinduced freezing test in experiment 11, rats were immediately killed, and their brains were prepared for autoradiography of CRH receptors in the L S. In addition, a few rats that received 100 ng of ␣hCRH into the L S before testing in the freezing chamber (n ϭ 5) were included in experiment 11 to compare brain sections from ␣hCRH-treated rats with those from N BI27914-treated rats in autoradiographic analyses. Because the behavioral data from these ␣hCRH-treated rats were identical to those from experiment 2, their freezing data are not displayed for the sake of brevity. Autoradiographic results from these animals are depicted in Figure 6 .
Histology
At the end of the experiments (except experiments 8 and 11), rats were given an overdose of pentobarbital (130 mg / kg) and perf used transcardially with isotonic saline followed by 10% formalin. Brains were removed, stored in formalin, and subsequently sectioned into 60 m coronal sections using a cryostat (Leica Instruments, Deerfield, IL). After staining with cresyl violet, sections were examined under a microscope for the location of injector tip placements. Animals whose injector placements fell outside of the targeted brain regions were excluded from analyses of behavioral data. At the time of histological verification of injector tip placements, the experimenter was blind to the pharmacological treatment as well as the behavioral data for each animal. For experiment 8, rats were deeply anesthetized with sodium pentobarbital and were then given a 5 l inf usion of Chicago blue dye (Sigma) through their ventricular cannulas. After a 3 min diffusion period, rats were decapitated, and brains were removed and sectioned into 2 mm slices. The appearance of dye within the ventricular system distal to the injection site was verified for each rat; rats without dye in their ventricles were excluded from analysis of behavioral data.
Autoradiography
For experiment 11, instead of perf usion, rats were killed by rapid decapitation immediately after they were tested in the freezing apparatus, and brains were quickly removed and frozen in chilled 2-methylbutane (Ϫ20 to Ϫ30°C). Brains were then mounted onto a cryostat block with Tissue-Tek (Hacker Instruments) and sectioned using a Leica cryostat. T wenty micrometer sections were thaw-mounted onto Fisher Scientific "plus-charged" slides, allowed to air dry, and stored at Ϫ80°C until use. On the day of assay, slides were thawed to room temperature and allowed to completely dry for a f urther 20 min. The area around each section was outlined using a grease marker, and 300 l of [
125 I]sauvagine (50 -100 pM final concentration in PBS containing 10 mM MgC l 2 and 2 mM EGTA, pH 7.0) was gently applied directly onto each section. Nonspecific binding was determined in adjacent sections by the addition of 1 M N BI27914, the selective CRH 1 receptor antagonist with a K i of 2 nM (Chen et al., 1996) , for the determination of the CRH 1 -specific binding, or 1 M D-Phe-CRH , which is an antagonist with equal affinity for the CRH 1 and CRH 2 receptors (K i , ϳ30 nM), in the buffer for determination of both CRH 1 and CRH 2 receptor-specific binding. The slides were placed in a covered humidified chamber to reduce evaporation and incubated at 22°C for 40 -45 min. After the incubation, the solution was gently aspirated from the section under vacuum, and the slides were washed using two 5 min dips in ice-cold PBS and Triton X-100 (0.01%), pH 7.0. Slides were then air-dried and apposed to Biomax MR x-ray film (Eastman Kodak Co., Rochester N Y) for 4 -5 d. Images were captured using a light box and digital camera (Northern Lights, St. C atharines, Ontario, C anada) and visualized using N IH Image (National Institutes of Health, Bethesda, MD). One set of adjacent sections from each animal was stained with cresyl violet and used to verif y the location of injector tips in the L S.
Data analysis
For all freezing experiments, the interval (in seconds) between the final foot shock and the commencement of freezing (latency to freeze) and the total number of seconds the rat spent freezing during the 15 min test session were calculated for each animal. In the analgesia experiment, the number of seconds (of a maximum of 60) that it took for the rat to lick its hindpaws after being placed on the hot plate was measured for each rat. Because freezing and analgesia data were not normally distributed (there was an upper limit to the scores imposed by the length of the testing session), nonparametric statistics were used to analyze these measures instead of parametric tests. For all freezing data, separate Mann -Whitney U tests (vehicle group vs drug group) were performed for each experiment. In experiment 10, where multiple comparisons were made, the ␣ level for statistical significance was adjusted to p Ͻ 0.02. Hot plate data were analyzed with a Wilcoxon matched pairs signed ranks test (vehicle vs drug treatment) because of the within-subjects design of this experiment. For locomotor activity data, the numbers of rears, ambulations (cage crossings), and total activity (total photo beam breaks) were calculated for each 10 min period of a 90 min test session. These data were analyzed with separate two-factor ANOVAs for each activity index, with drug treatment and time point as within-subjects factors.
RESULTS

Effects on freezing of CRH 1 /CRH 2 receptor antagonist infusion into the LS
The results of experiment 1 are displayed in Figure 1C . Infusion of 30 ng of ␣hCRH into the LS had no effect on either index of freezing behavior (latency to freeze, p ϭ 0.427; total duration of freezing, p ϭ 0.705, Mann-Whitney U test). In contrast, a higher dose of ␣hCRH (100 ng/side) significantly increased the latency to begin freezing ( p Ͻ 0.004) and decreased the total duration of freezing ( p Ͻ 0.018) after infusion into the LS (experiment 2, seen in Fig. 1 A) . Rats that received 100 ng of ␣hCRH took approximately three times as long to begin freezing and spent approximately half as much time freezing compared with vehicletreated controls. As depicted in Figure 1 B, ␣hCRH decreased freezing in the first as well as the second and third portions of the test session, indicating that this reduction was not simply attributable to the antagonist-induced increase in the latency to begin freezing. Thus, infusion of 100 ng of ␣hCRH into the LS significantly reduced this measure of stress-induced behavior. Interestingly, infusion of a higher dose of ␣hCRH into the LS (experiment 3; 300 ng) failed to affect either the latency to freeze ( p ϭ 0.748) or the total duration of freezing ( p ϭ 0.521), indicating that ␣hCRH displays an inverted U-shaped dose-response profile for reducing shock-induced freezing in the LS (Fig. 1 D) . Finally, Figure 1 E illustrates the results of experiment 4, which demonstrated that another more potent CRH 1 /CRH 2 receptor antagonist, D-Phe-CRH , also increased the latency to freeze ( p Ͻ 0.011) and decreased the total duration of freezing after infusion into the LS ( p Ͻ 0.05). This reduction in freezing also occurred throughout the test session (Fig. 1 F) . It should be noted that this decrease in freezing was identical to that seen with ␣hCRH and that the latency and total freezing values in vehicle-treated rats in both experiments were similar. This similarity in profile between experiments 2 and 4 indicates that no effect on freezing latency or duration was produced by using a 1.0 versus a 1.5 mA shock intensity. These findings with D-Phe-CRH confirm the results with ␣hCRH and furthermore indicate that behavioral effects of these antagonists in the LS cannot be attributed to indirect actions mediated through the CRH-binding protein, which binds with moderate affinity to ␣hCRH but has no affinity for D-Phe-CRH .
Effects on locomotor activity and analgesia of intra-LS ␣hCRH infusion
In contrast to the potent effects on shock-induced freezing behavior, ␣hCRH infusion into the LS produced no changes in locomotor activity (experiment 5). ANOVAs failed to indicate main effects of ␣hCRH on rearing [F (3,30) Moreover, no significant treatment ϫ time interactions were seen. Because the effects were identical for all three indices of locomotor activity, only the data for total activity counts (total photobeam breaks) are displayed (Fig. 2 A) . Similarly, in experiment 6, D-Phe-CRH failed to affect any index of locomotor activity; total activity counts are shown in Figure 2 B [F (1,10) ϭ 0.10; NS]. Analysis of data from experiment 7 indicated that pain thresholds were similarly unaffected by infusion of 100 ng of ␣hCRH into the LS (Fig. 2C) . A Wilcoxon signed ranks test revealed that the latency to lick hindpaws after being placed on the hot plate did not differ between the vehicle condition and the drug condition 3 min ( p ϭ 0.917), 10 min ( p ϭ 0.631), or 15 min ( p ϭ 0.464) after infusion, thereby mapping out the time course of the freezing test. Thus, intra-LS infusion of ␣hCRH had no effect on pain thresholds or locomotor activity at any time during the length of the freezing test session, suggesting that changes in shockinduced freezing that were produced by this treatment were not simply an artifact of altered sensitivity to the foot shock or altered baseline activity levels. Figure 3 depicts the effects on shock-induced freezing of 100 ng of ␣hCRH infusion into either the LV or the NDB. Mann-Whitney U tests indicated that for the LV, ␣hCRH-treated rats performed no differently from vehicle-treated rats on either the latency to begin freezing ( p ϭ 0.965) or the total duration of freezing ( p ϭ 0.453) (experiment 8, seen in Fig. 3A) . Likewise, it is shown in Figure 3B that infusion of ␣hCRH into the NDB (experiment 9) had no effect on either measure of freezing ( p ϭ 0.894 for latency, and p ϭ 0.248 for total duration). Thus, although this dose of ␣hCRH markedly reduced freezing on intra-LS infusion, it had no effect on shock-induced freezing when delivered into regions that are adjacent to the LS, suggesting that the effects of ␣hCRH after intra-LS infusion were not mediated by actions at other adjacent brain regions. 
Effects on freezing of ␣hCRH infusion into sites adjacent to the LS
Effects of a selective CRH 1 receptor antagonist on freezing
The effects on freezing of NBI27914 (a selective CRH 1 antagonist) administration into the CeA were investigated in experiment 10 (Fig. 4 A) . It was found that the 1.0 g dose ( p ϭ 0.015) but not the 0.2 g dose ( p ϭ 0.037) significantly increased the latency to begin freezing after NBI27914 infusion into the CeA. The high ( p ϭ 0.010) but not the low ( p ϭ 0.150) dose of NBI27914 also decreased the total duration of freezing after intra-CeA infusion; freezing was reduced throughout the test (Fig. 4 B) . Thus, infusion of a highly selective CRH 1 antagonist into the CeA profoundly reduced shock-induced freezing, suggesting that within this structure, the CRH 1 receptor subtype at least in part mediates stress-induced behavioral responses. In contrast, when infused into the LS, NBI27914 had no effect on the latency to begin freezing ( p ϭ 0.338) or the total duration of freezing ( p ϭ 0.655) (experiment 11; Fig. 4C ). Thus, a dose of a CRH 1 receptor antagonist that markedly reduced freezing on intra-CeA infusion failed to alter this behavior when infused into the LS. Figure 5 displays the location of injector tips in the various brain regions that were studied. Injector tips for all animals except two in the LS experiments, one in the NDB experiment, and one in the CeA experiment were found to be within the targeted regions. Data from these anatomical outliers were excluded from statistical analysis; the sample sizes reported in Materials and Methods reflect the omission of these rats. The photomicrographs in Figure 5 depict a section from each brain region under investigation; the location of injector tips in these images is representative of placements within that region. As can be seen in Figure  5 , excessive tissue damage was not observed with infusion into any region.
Histological analysis
Autoradiography for CRH receptors in the LS
Ex vivo receptor autoradiography was used as described above for assessing [ 125 I]sauvagine binding in brain sections from animals that had received either vehicle or CRH receptor antagonists into the LS. This analytical technique was used to provide a qualitative assessment of relative levels of [
125 I]sauvagine binding in sections from different treatment groups. It should be noted that although there is some unavoidable variability in the precise rostral-caudal location of the selected sections, these differences are small (ϳ100 m), and that CRH 2␣ receptors are distributed homogeneously throughout the entire extent of the LS (Chalmers et al., 1995) . Thus, the sections displayed in the following figures provide a representative example of receptor labeling within this structure after various CRH antagonist treatments. Figure 6 displays representative sections from rats that were given vehicle (Fig. 6 A) , 1 g of NBI27914 (Fig. 6 B) , or 100 ng of ␣hCRH (Fig. 6C ) directly into the LS before behavioral testing. The binding of [
125 I]Tyr 0 sauvagine to CRH receptors in the LS was nearly undetectable in rats that had received the nonselective antagonist ␣hCRH into this region (Fig. 6C) . As can be seen clearly in Figure 6 B, there was no inhibition of [
125 I]sauvagine binding in the LS in animals that had received intra-LS NBI27914; the level of binding in NBI27914-treated rats was equivalent to that observed in vehicle-treated rats (Fig. 6 A) . Thus, the observation that a mixed CRH 1 /CRH 2 (␣hCRH) antagonist prevented radioligand binding in the LS but a selective CRH 1 antagonist did not suggests that the CRH receptor to which the infused ␣hCRH is binding is of the CRH 2␣ subtype. (Fig. 7A) or the presence of 1 M NBI27914 (Fig. 7B ) or 1 M D-Phe-CRH (Fig. 7C) . In the presence of 1 M NBI27914, [ 125 I]sauvagine binding was inhibited from CRH 1 receptors in the cortex, with no observable inhibition of binding to CRH 2 receptors in the LS (arrows). In contrast, in the presence of D-Phe-CRH , the nonselective CRH 1 /CRH 2 antagonist, radioligand binding was virtually abolished in both the cortical and septal areas (Fig. 7C) . Note the faint intensity of the radioactive signal in Figure 7C ; areas that appear light or white indicate that little or no [
125 I]Tyr 0 sauvagine bound to this section, suggesting that incubation with the unlabeled D-Phe-CRH caused nearly all CRH receptors to become occupied and therefore unavailable for [
125 I]Tyr 0 sauvagine binding. These results confirm that the identity of CRH receptors within the LS is of the CRH 2 but not the CRH 1 receptor subtype. These data are consistent with previous reports indicating that there is a high density of CRH 2␣ receptors in the LS, but that this structure is devoid of CRH 1 receptors (Chalmers et al., 1995; Primus et al., 1997) . Taken together, these findings indicate that the behavioral actions of intra-LS ␣hCRH infusion are likely mediated through CRH 2␣ and not CRH 1 receptors.
DISCUSSION
In the present studies, microinfusion of the CRH 1 /CRH 2 receptor antagonist ␣hCRH into the LS decreased shock-induced freezing, a measure of stress-induced behavior, without affecting general activity levels or pain sensitivity. The same dose that decreased freezing on intra-LS infusion had no effect after infusion into neighboring regions such as the LV or NDB. An identical pattern of results was obtained with the more potent CRH 1 /CRH 2 receptor antagonist D-Phe-CRH . In contrast, a highly selective CRH 1 receptor antagonist that reduced freezing after intra-CeA infusion failed to affect freezing when infused into the LS. Moreover, intra-LS administration of the CRH 1 -selective antagonist did not affect ex vivo binding of 
In vitro studies demonstrated that [
125 I]sauvagine binding in the LS was not affected after incubating sections with excess CRH 1 antagonist but was abolished after incubating sections with excess CRH 1 /CRH 2 receptor antagonist. These results confirm that on intra-LS infusion, the actions of ␣hCRH on freezing can be attributed to the interaction of this antagonist with the CRH 2␣ receptor. Taken together, these findings indicate that blockade of CRH 2␣ but not CRH 1 receptors within the LS decreases stressinduced behavior. To the best of our knowledge, this is the first report to show that the acute and selective antagonism of CRH 2␣ receptors reduces stress-induced defensive behavior.
The behavioral specificity of the CRH antagonist-induced reduction in freezing is supported by the finding that locomotor activity (irrespective of whether rats were previously habituated to the testing chambers) and pain sensitivity (regardless of the postinfusion time point for testing) were not affected by ␣hCRH or D-Phe-CRH . The finding that a separate CRH receptor antagonist, D-Phe-CRH , produced the exact same behavioral profile as ␣hCRH provides independent corroboration for the notion that blockade of CRH receptors within the LS causes a reduction specifically in stress-like behavior. CRH receptor blockade caused an increase in the latency to begin freezing and a decrease in the duration of freezing at each time point of the test, indicating that this reduction in stress-induced freezing was long-lasting and occurred throughout the entire extent of the test session. The finding that a selective CRH 1 antagonist blocked freezing when infused into the CeA but failed to alter freezing after intra-LS infusion provides novel and clear evidence (in conjunction with the autoradiographic findings) that within the LS, it is the antagonism of specifically the CRH 2␣ receptor subtype that reduces stress-induced behavior.
The present studies thus indicate that the LS is an important site for the regulation of stress-induced freezing. The finding that 100 ng of ␣hCRH reduced freezing on intra-LS infusion but failed to alter this behavior after intracerebroventricular administration is particularly striking, given that the lateral ventricle borders the LS. Our previous work indicates that 25 g of this antagonist is required to reduce shock-induced freezing via intracerebroventricular administration (Kalin et al., 1988) . Thus, the failure of 100 ng of ␣hCRH to reduce freezing after intracerebroventricular administration likely indicates that ␣hCRH-induced effects observed in LS-treated rats were highly anatomically specific to the LS and did not arise from diffusion of the antagonist into the ventricle or other brain regions. One interesting feature of the ␣hCRH dose-response profile was its inverted U shape with regard to freezing; a middle dose but neither a low nor high dose reduced this stress-induced behavior after infusion into the LS. Although the specific mechanisms underlying this profile remain to be determined, it should be noted that an identical dose-response profile for ␣hCRH on shock-induced freezing has been observed previously for the CeA (Swiergiel et al., 1993) .
The present findings extend previous reports indicating that ␣hCRH infusion into locus ceruleus or CeA decreases shockinduced freezing behavior (Swiergiel et al., 1992 (Swiergiel et al., , 1993 . CRH receptor antagonism within the CeA also prevents behaviors induced by a variety of other different stressors (Heinrichs et al., 1992; Rassnick et al., 1993) . The present results further these findings by indicating that within the CeA, the reduction of stress-induced behavior is likely mediated through blockade of the CRH 1 receptor subtype. Moreover, the present findings suggest that decreases in stress-induced behaviors after CRH 1 receptor knock-out or systemic CRH 1 receptor antagonist administration may involve the CeA (Smith et al., 1998; Timpl et al., 1998; Contarino et al., 1999; Okuyama et al., 1999; Habib et al., 2000) . It is thus possible that the recently described clinical efficacy of CRH 1 receptor antagonists in depression (Zobel et al., 2000) involves the blockade of CRH 1 receptors within the CeA. To the best of our knowledge, the present report is the first to identify the specific neuroanatomical substrates through which the different CRH receptor subtypes regulate defensive freezing.
It could be argued that the decreased freezing seen after intra-LS ␣hCRH infusion may result from diffusion of the drug into the medial septum (MS), a structure devoid of CRH 2␣ receptors but enriched in CRH 1 receptors (Chalmers et al., 1995) . This possibility is unlikely, however, given that intra-LS NBI27914 infusion (which could diffuse to the MS and block CRH 1 receptors) and intra-NDB ␣hCRH infusion (which would be equally likely to diffuse to the MS as would intra-LS ␣hCRH) failed to alter shock-induced freezing. Thus, it seems that although both CRH 1 and CRH 2␣ receptors regulate stress-induced behaviors, they act through different brain regions. The present findings are in agreement with a previous report in which intra-LS administration of a putative CRH 2 -preferring antagonist [anti-sauvagine-30 (AS30)] was found to reverse stress-or CRH-induced decreases in open arm entries in an elevated plusmaze in mice (Ruhmann et al., 1998; Radulovic et al., 1999) . High doses of AS30 have also been reported to decrease freezing behavior after intracerebroventricular infusion (Takahashi et al., 2001) , further corroborating the findings of the present study, yet there are conflicting reports about the CRH 2 selectivity of AS30 (Ruhmann et al., 1998; Higelin et al., 2001 ). The present studies therefore clarify these previous behavioral findings by systematically demonstrating that reductions in stress-induced behavior caused by CRH antagonist administration into the LS are attributable to the CRH 2␣ and not the CRH 1 receptor. Furthermore, the present findings indicate that these two receptor subtypes may regulate stress-induced behavior through different anatomical sites.
In contrast to the findings with acute CRH 2␣ receptor antagonism, CRH 2␣ knock-out mice exhibit higher levels of stressinduced behaviors than wild-type controls, although this profile is not consistent across behavioral paradigms or across different laboratories (Bale et al., 2000; Coste et al., 2000; Kishimoto et al., 2000) . A major difficulty in interpreting the results of constitutive gene knock-out studies is that the animal matures without the gene of interest and can develop compensatory alterations that contribute to the final behavioral phenotype (Picciotto and Wickman, 1998; Gingrich and Hen, 2000) . Thus, the stress-like behavioral phenotype observed in the CRH 2␣ knock-out mice might not derive directly from the absence of the CRH 2␣ receptor but rather may be caused through indirect compensatory alterations in the CRH and other systems. Increased gene expression of CRH (in the CeA) and the CRH-like ligand urocortin has been reported in CRH 2␣ knock-out mice (Bale et al., 2000; Coste et al., 2000) . Urocortin decreases feeding and increases stress-like responding in certain approach-avoidance-based behavioral tests (Spina et al., 1996; Moreau et al., 1997; Jones et al., 1998; Cullen et al., 2001) . Likewise, the present findings indicate that stimulation of CRH 1 receptors in the CeA would increase stress-like responses. The very novel discovery of CRH 2 -selective members of the CRH family of endogenous ligands (urocortin II, urocortin III, and stresscopin) offers an even more complex picture of the potential compensatory effects within this system (Hsu and Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001 al., 2000) will aid in clarifying the contributions of developmental factors to the phenotype produced by CRH 2␣ receptor knock-out.
One previous report indicates that subchronic exposure to benzodiazepines decreased CRH 1 receptor levels but increased CRH 2␣ receptor levels in rat brain, indicating that CRH 1 and CRH 2␣ receptors may act in an opposing manner (Skelton et al., 2000) . It has been suggested that CRH 2␣ receptors are involved in "coping" with stress rather than in the direct behavioral response to stress, which is hypothesized to be mediated by CRH 1 receptors (Liebsch et al., 1999) . The present results, however, indicate that CRH 1 and CRH 2␣ receptors play similar or parallel roles in the regulation of stress-related behavior, and that this regulation may occur through different brain regions. It may be that the CRH receptor subtypes are differentially affected by long-term drug treatment but that their roles in mediating acute stressinduced behavioral effects are similar.
The present finding that acute blockade of CRH 2␣ receptors within the LS decreases stress-induced freezing is not surprising if one considers the electrophysiological role of CRH in the LS and the role of the LS in regulating defensive behaviors. Singleunit recordings from the LS indicate that within this structure, CRH is inhibitory (Siggins et al., 1985) ; the LS is thought to provide a tonic inhibition over the expression of defensive behaviors Walsh, 1982, 1984; Graeff, 1994) . Thus, stimulation of CRH receptors within the LS (perhaps through stressinduced CRH or urocortin release) might be expected to disinhibit defensive behaviors such as freezing. Antagonism of these receptors would prevent this disinhibition and would maintain the tonic inhibition over defensive behaviors, thereby reducing the expression of freezing.
The precise circuitry through which CRH 1 and CRH 2␣ receptors interact to control stress-related behaviors remains to be determined. The LS is important in modulating defensive behaviors (Graeff, 1994) , and the CeA regulates the expression of fear-related responses (Davis and Shi, 1999) . The present studies indicate that antagonism of CRH 2␣ receptors within the LS or CRH 1 receptors within the CeA decreases the expression of fear-induced defensive behavior. In rats, both the LS and CeA receive CRH-or urocortin-containing terminals (Swanson et al., 1983; Sakanaka et al., 1988; Kozicz et al., 1998; Bittencourt et al., 1999) . In addition, anatomical tract-tracing studies indicate reciprocal connections between these two structures (Risold and Swanson, 1997) and also indicate that both structures project to the periaqueductal gray (PAG; Rizvi et al., 1991; Risold and Swanson, 1997) , a midbrain structure that, when stimulated, elicits defensive behaviors such as freezing (Bandler et al., 1985; Behbehani, 1995) . Because stress-induced freezing is a defensive behavior necessary for an organism's survival, it may be adaptive to have parallel systems involving the two CRH receptor subtypes that can either independently or interactively modulate the expression of this critical form of behavioral inhibition. It is possible that information from the CRH 2␣ -LS system and the CRH 1 -CeA system converges within the PAG to regulate the expression of freezing. Although further studies must be performed to test this hypothesis, the present findings provide a valuable starting point for identifying the specific role of CRH receptor subtypes in the neuroanatomical circuitry subserving stress-related defensive behaviors.
Because increased CRH activity has been hypothesized to play a role in mediating anxiety and depressive disorders, there has been much emphasis on developing new antidepressant or anxiolytic drugs that antagonize CRH receptors (McCarthy et al., 1999) . CRH 1 receptor antagonists have shown some preliminary success in an open-label clinical trial as a novel class of antidepressants (Zobel et al., 2000) . Anxiety disorders and depression have been conceptualized as an aberrant manifestation of adaptive stress-or fear-related defensive behaviors (Bakshi and Kalin, 2002) . The present results indicate that acute antagonism of CRH 2␣ receptors reduces stress-induced defensive behavior. This receptor subtype may thus play an important role in mediating aberrant expressions of fear-related responses that become dysregulated in stress-related disorders such as anxiety or depression. Thus, in addition to the CRH 1 receptor, attention should also be focused on the development of nonpeptide CRH 2␣ receptor antagonists, which could be useful as therapeutic agents for stress-related psychopathology.
